Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Richard Granneman
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Procedures
Physiology
Concepts & Ideas
Chemicals & Drugs
Sign-in to see full Profile
Network (preview)
17
Locke, Charles
16
Cavanaugh, John
14
Awni, Walid
11
Hsu, Ann
8
Cao, Guoliang
8
Dubé, LM
8
Dutta, Sandeep
8
Samara, Emil
8
Leonard, JM
7
Wong, SL
6
Sörgel, Fritz
6
Sun, Eugene
6
Witt, GF
5
Mack, RJ
5
Kempf, Dale
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Richard Granneman (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2006: Reed Ronald C; Dutta Sandeep; Cavanaugh John H; Locke Charles; Granneman G Richard
Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations.
Epilepsy & behavior : E&B 2006;8(2):391-6.
-
2005: Dutta Sandeep; Qiu Yihong; Samara Emil; Cao Guoliang; Granneman G Richard
Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC).
Journal of pharmaceutical sciences 2005;94(9):1949-56.
-
2004: Blakesley Vicky; Awni Walid; Locke Charles; Ludden Thomas; Granneman G Richard; Braverman Lewis E
Are bioequivalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable?
Thyroid : official journal of the American Thyroid Association 2004;14(3):191-200.
-
2003: Dutta Sandeep; Cloyd James C; Granneman G Richard; Collins Stephen D
Oral/intravenous maintenance dosing of valproate following intravenous loading: a simulation.
Epilepsy research 2003;53(1-2):29-38.
-
2003: Cloyd James C; Dutta Sandeep; Cao Guoliang; Walch Julia K; Collins Stephen D; Granneman G Richard;
Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy.
Epilepsy research 2003;53(1-2):19-27.
-
2003: Hsu Ann; Isaacson Jeffrey; Brun Scott; Bernstein Barry; Lam Wayne; Bertz Richard; Foit Cheryl; Rynkiewicz Karen; Richards Bruce; King Martin; Rode Richard; Kempf Dale J; Granneman G Richard; Sun Eugene
Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.
Antimicrobial agents and chemotherapy 2003;47(1):350-9.
-
2002: Dutta Sandeep; Zhang Yiming; Daszkowski Daniel J; Granneman G Richard; Verlinden Marleen
Single- and multiple-dose pharmacokinetics of fiduxosin under nonfasting conditions in healthy male subjects.
Journal of clinical pharmacology 2002;42(5):540-6.
-
2002: Dutta Sandeep; Zhang Yiming; Daszkowski Daniel J; Granneman G Richard; Verlinden Marleen
Multiple dose pharmacokinetics of fiduxosin under fasting conditions in healthy elderly male subjects.
The Journal of pharmacy and pharmacology 2002;54(5):641-7.
-
2002: Dutta Sandeep; Zhang Yiming; Granneman G Richard; Verlinden Marleen
Effect of food on the pharmacokinetics of fiduxosin in healthy male subjects.
European journal of drug metabolism and pharmacokinetics 2002;27(1):49-52.
-
2001: Samara E; Dutta S; Cao G; Granneman G R; Dordal M S; Padley R J
Single-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist.
Journal of clinical pharmacology 2001;41(4):397-403.
-
1999: Kumar G N; Dykstra J; Roberts E M; Jayanti V K; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman G R
Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(8):902-8.
-
1998: Wong S L; Granneman G R
Modeling of sertindole pharmacokinetic disposition in healthy volunteers in short term dose-escalation studies.
Journal of pharmaceutical sciences 1998;87(12):1629-31.
-
1998: Sham H L; Kempf D J; Molla A; Marsh K C; Kumar G N; Chen C M; Kati W; Stewart K; Lal R; Hsu A; Betebenner D; Korneyeva M; Vasavanonda S; McDonald E; Saldivar A; Wideburg N; Chen X; Niu P; Park C; Jayanti V; Grabowski B; Granneman G R; Sun E; Japour A J; Leonard J M; Plattner J J; Norbeck D W
ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.
Antimicrobial agents and chemotherapy 1998;42(12):3218-24.
-
1998: Ouellet D; Hsu A; Qian J; Lamm J E; Cavanaugh J H; Leonard J M; Granneman G R
Effect of fluoxetine on pharmacokinetics of ritonavir.
Antimicrobial agents and chemotherapy 1998;42(12):3107-12.
-
1998: Hsu A; Granneman G R; Cao G; Carothers L; Japour A; El-Shourbagy T; Dennis S; Berg J; Erdman K; Leonard J M; Sun E
Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers.
Antimicrobial agents and chemotherapy 1998;42(11):2784-91.
-
1998: Hsu A; Granneman G R; Bertz R J
Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.
Clinical pharmacokinetics 1998;35(4):275-91.
-
1998: Ouellet D; Hsu A; Granneman G R; Carlson G; Cavanaugh J; Guenther H; Leonard J M
Pharmacokinetic interaction between ritonavir and clarithromycin.
Clinical pharmacology and therapeutics 1998;64(4):355-62.
-
1998: Ouellet D; Hsu A; Qian J; Locke C S; Eason C J; Cavanaugh J H; Leonard J M; Granneman G R
Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers.
British journal of clinical pharmacology 1998;46(2):111-6.
-
1998: Samara E E; Gustavson L E; El-Shourbagy T; Locke C; Granneman G R; Sommerville K W
Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy.
Epilepsia 1998;39(8):868-73.
-
1998: Molla A; Granneman G R; Sun E; Kempf D J
Recent developments in HIV protease inhibitor therapy.
Antiviral research 1998;39(1):1-23.
-
1998: Hsu A; Granneman G R; Cao G; Carothers L; el-Shourbagy T; Baroldi P; Erdman K; Brown F; Sun E; Leonard J M
Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir.
Clinical pharmacology and therapeutics 1998;63(4):453-64.
-
1998: Gustavson L E; Sommerville K W; Boellner S W; Witt G F; Guenther H J; Granneman G R
Lack of a clinically significant pharmacokinetic drug interaction between tiagabine and valproate.
American journal of therapeutics 1998;5(2):73-9.
-
1998: Wong S L; Cao G; Mack R; Granneman G R
Lack of CYP3A inhibition effects of sertindole on terfenadine in healthy volunteers.
International journal of clinical pharmacology and therapeutics 1998;36(3):146-51.
-
1998: Wong S L; Locke C; Staser J; Granneman G R
Lack of multiple dosing effect of sertindole on the pharmacokinetics of alprazolam in healthy volunteers.
Psychopharmacology 1998;135(3):236-41.
-
1997: Wong S L; Cao G; Mack R J; Granneman G R
The effect of erythromycin on the CYP3A component of sertindole clearance in healthy volunteers.
Journal of clinical pharmacology 1997;37(11):1056-61.
-
1997: Samara E; Cao G; Locke C; Granneman G R; Dean R; Killian A
Population analysis of the pharmacokinetics and pharmacodynamics of seratrodast in patients with mild to moderate asthma.
Clinical pharmacology and therapeutics 1997;62(4):426-35.
-
1997: Wong S L; Cao G; Mack R J; Granneman G R
Pharmacokinetics of sertindole in healthy young and elderly male and female subjects.
Clinical pharmacology and therapeutics 1997;62(2):157-64.
-
1997: Wong S L; Linnen P; Mack R; Granneman G R
Effects of food, antacid, and dosage form on the pharmacokinetics and relative bioavailability of sertindole in healthy volunteers.
Biopharmaceutics & drug disposition 1997;18(6):533-41.
-
1997: Hsu A; Granneman G R; Witt G; Locke C; Denissen J; Molla A; Valdes J; Smith J; Erdman K; Lyons N; Niu P; Decourt J P; Fourtillan J B; Girault J; Leonard J M
Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects.
Antimicrobial agents and chemotherapy 1997;41(5):898-905.
-
1997: Gustavson L E; Boellner S W; Granneman G R; Qian J X; Guenther H J; el-Shourbagy T; Sommerville K W
A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures.
Neurology 1997;48(4):1032-7.
-
1997: Bertz R J; Granneman G R
Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.
Clinical pharmacokinetics 1997;32(3):210-58.
-
1997: Kempf D J; Marsh K C; Kumar G; Rodrigues A D; Denissen J F; McDonald E; Kukulka M J; Hsu A; Granneman G R; Baroldi P A; Sun E; Pizzuti D; Plattner J J; Norbeck D W; Leonard J M
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.
Antimicrobial agents and chemotherapy 1997;41(3):654-60.
-
1997: Tamminga C A; Mack R J; Granneman G R; Silber C J; Kashkin K B
Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety.
International clinical psychopharmacology 1997;12 Suppl 1():S29-35.
-
1997: Wong S L; Menacherry S; Mulford D; Schmitz P J; Locke C; Granneman G R
Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function.
European journal of clinical pharmacology 1997;52(3):223-7.
-
1996: Samara E E; Hosmane B; Locke C; Eason C; Cavanaugh J; Granneman G R
Assessment of the pharmacokinetic-pharmacodynamic interaction between terazosin and finasteride.
Journal of clinical pharmacology 1996;36(12):1169-78.
-
1996: Wong S L; Cavanaugh J; Shi H; Awni W M; Granneman G R
Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics.
Clinical pharmacology and therapeutics 1996;60(1):48-53.
-
1996: Molla A; Korneyeva M; Gao Q; Vasavanonda S; Schipper P J; Mo H M; Markowitz M; Chernyavskiy T; Niu P; Lyons N; Hsu A; Granneman G R; Ho D D; Boucher C A; Leonard J M; Norbeck D W; Kempf D J
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir.
Nature medicine 1996;2(7):760-6.
-
1996: Granneman G R; Schneck D W; Cavanaugh J H; Witt G F
Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium.
The Journal of clinical psychiatry 1996;57(5):204-6.
-
1995: Granneman G R; Karol M D; Locke C S; Cavanaugh J H
Pharmacokinetic interaction between lansoprazole and theophylline.
Therapeutic drug monitoring 1995;17(5):460-4.
-
1995: Karol M D; Granneman G R; Alexander K
Determination of lansoprazole and five metabolites in plasma by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;668(1):182-6.
-
1995: St Peter J V; Braeckman R A; Granneman G R; Locke C S; Cavanaugh J H; Awni W M
The effect of zileuton on antipyrine and indocyanine green disposition.
Clinical pharmacology and therapeutics 1995;57(3):299-308.
-
1995: Awni W M; Braeckman R A; Locke C S; Dubé L M; Granneman G R
The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine.
Clinical pharmacokinetics 1995;29 Suppl 2():98-104.
-
1995: Awni W M; Hussein Z; Cavanaugh J H; Granneman G R; Dubé L M
Assessment of the pharmacokinetic interaction between zileuton and digoxin in humans.
Clinical pharmacokinetics 1995;29 Suppl 2():92-7.
-
1995: Samara E; Cavanaugh J H; Mukherjee D; Granneman G R
Lack of pharmacokinetic interaction between zileuton and phenytoin in humans.
Clinical pharmacokinetics 1995;29 Suppl 2():84-91.
-
1995: Granneman G R; Braeckman R A; Locke C S; Cavanaugh J H; Dubé L M; Awni W M
Effect of zileuton on theophylline pharmacokinetics.
Clinical pharmacokinetics 1995;29 Suppl 2():77-83.
-
1995: Awni W M; Hussein Z; Granneman G R; Patterson K J; Dubé L M; Cavanaugh J H
Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans.
Clinical pharmacokinetics 1995;29 Suppl 2():67-76.
-
1995: Awni W M; Cavanaugh J H; Witt G; Granneman G R; Dubé L M
The effect of food on the pharmacokinetics of zileuton.
Clinical pharmacokinetics 1995;29 Suppl 2():62-6.
-
1995: Awni W M; Cavanaugh J H; Braeckman R A; Chu S Y; Patterson K J; Machinist J M; Granneman G R
The effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileuton.
Clinical pharmacokinetics 1995;29 Suppl 2():49-61.
-
1995: Braeckman R A; Granneman G R; Locke C S; Machinist J M; Cavannaugh J H; Awni W M
The pharmacokinetics of zileuton in healthy young and elderly volunteers.
Clinical pharmacokinetics 1995;29 Suppl 2():42-8.
-
1995: Awni W M; Braeckman R A; Granneman G R; Witt G; Dubé L M
Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers.
Clinical pharmacokinetics 1995;29 Suppl 2():22-33.
-
1995: Awni W M; Braeckman R A; Cavanaugh J H; Locke C S; Linnen P J; Granneman G R; Dubé L M
The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers.
Clinical pharmacokinetics 1995;29 Suppl 2():112-24.
-
1995: Awni W M; Cavanaugh J H; Tzeng T B; Witt G; Granneman G R; Dubé L M
Pharmacokinetic interactions between zileuton and prednisone.
Clinical pharmacokinetics 1995;29 Suppl 2():105-11.
-
1995: Granneman G R; Braeckman R A; Erdman K A
Determination of a new 5-lipoxygenase inhibitor, zileuton, and its inactive N-dehydroxylated metabolite in plasma by high performance liquid chromatography.
Clinical pharmacokinetics 1995;29 Suppl 2():1-8.
-
1995: Awni W M; Granneman G R; Locke C S; Brandwein S R; Dube L M
Population pharmacokinetics of zileution, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis.
European journal of clinical pharmacology 1995;48(2):155-60.
-
1994: Hussein Z; Mukherjee D; Lamm J; Cavanaugh J H; Granneman G R
Pharmacokinetics of valproate after multiple-dose oral and intravenous infusion administration: gastrointestinal-related diurnal variation.
Journal of clinical pharmacology 1994;34(7):754-9.
-
1994: Hussein Z; Samara E; Locke C S; Orchard M A; Ringham G L; Granneman G R
Characterization of the pharmacokinetics and pharmacodynamics of a new oral thromboxane A2-receptor antagonist AA-2414 in normal subjects: population analysis.
Clinical pharmacology and therapeutics 1994;55(4):441-50.
-
1993: Hussein Z; Granneman G R; Mukherjee D; Samara E; Hogan D L; Koss M A; Isenberg J I
Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole.
British journal of clinical pharmacology 1993;36(5):391-8.
-
1993: Hussein Z; Mulford D J; Bopp B A; Granneman G R
Stereoselective pharmacokinetics of pazinaclone, a new non-benzodiazepine anxiolytic, and its active metabolite in healthy subjects.
British journal of clinical pharmacology 1993;36(4):357-61.
-
1993: Hussein Z; Mulford D J; Bopp B A; Granneman G R
Differences in the stereoselective pharmacokinetics of pazinaclone (DN-2327), a new anxiolytic, and its active metabolite after intravenous and oral single doses to dogs.
Drug metabolism and disposition: the biological fate of chemicals 1993;21(5):805-10.
-
1993: Hussein Z; Patterson K J; Lamm J E; Cavanaugh J H; Granneman G R
Effect of infusion duration on valproate pharmacokinetics.
Biopharmaceutics & drug disposition 1993;14(5):389-99.
-
1993: Chu S Y; Granneman G R; Pichotta P J; Decourt J P; Girault J; Fourtillan J B
Effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics.
Journal of clinical pharmacology 1993;33(5):480-5.
-
1993: Gupta S K; Granneman G R; Packer M; Boger R S
Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a renin inhibitor). II: A dose-ranging study in patients with congestive heart failure.
Journal of cardiovascular pharmacology 1993;21(5):834-40.
-
1993: Hussein Z; Chu S Y; Granneman G R
Enantioselective determination of DN-2327, a novel non-benzodiazepine anxiolytic, and/or its active metabolite in human plasma and urine using high-performance liquid chromatography.
Journal of chromatography 1993;613(1):113-20.
-
1993: Hussein Z; Chu S Y; Granneman G R
High-performance liquid chromatographic method for determination of DN-2327, a novel non-benzodiazepine anxiolytic, and/or its active metabolite in human plasma and urine.
Journal of chromatography 1993;613(1):105-12.
-
1992: Gupta S K; Granneman G R; Boger R S; Hollenberg N K; Luther R R
Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a new renin inhibitor). I: Single dose study.
Drug metabolism and disposition: the biological fate of chemicals 1992;20(6):821-5.
-
1992: Granneman G R; Carpentier P; Morrison P J; Pernet A G
Pharmacokinetics of temafloxacin in humans after multiple oral doses.
Antimicrobial agents and chemotherapy 1992;36(2):378-86.
-
1992: Mahr G; Sörgel F; Granneman G R; Kinzig M; Muth P; Patterson K; Fuhr U; Nickel P; Stephan U
Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine.
Clinical pharmacokinetics 1992;22 Suppl 1():90-7.
-
1992: Granneman G R; Stephan U; Birner B; Sörgel F; Mukherjee D
Effect of antacid medication on the pharmacokinetics of temafloxacin.
Clinical pharmacokinetics 1992;22 Suppl 1():83-9.
-
1992: Sörgel F; Granneman G R; Stephan U; Locke C
Effect of cimetidine on the pharmacokinetics of temafloxacin.
Clinical pharmacokinetics 1992;22 Suppl 1():75-82.
-
1992: Sörgel F; Mahr G; Granneman G R; Stephan U; Nickel P; Muth P
Effects of 2 quinolone antibacterials, temafloxacin and enoxacin, on theophylline pharmacokinetics.
Clinical pharmacokinetics 1992;22 Suppl 1():65-74.
-
1992: Granneman G R; Mukherjee D
The effect of food on the bioavailability of temafloxacin. A review of 3 studies.
Clinical pharmacokinetics 1992;22 Suppl 1():48-56.
-
1992: Sörgel F; Granneman G R; Mahr G; Kujath P; Fabian W; Nickel P
Hepatobiliary elimination of temafloxacin.
Clinical pharmacokinetics 1992;22 Suppl 1():33-42.
-
1992: Granneman G R; Mahr G; Locke C; Nickel P; Kirch W; Fabian W; Kinzig M; Naber K G; Sörgel F
Pharmacokinetics of temafloxacin in patients with liver impairment.
Clinical pharmacokinetics 1992;22 Suppl 1():24-32.
-
1992: Granneman G R
Pharmacokinetics of temafloxacin after multiple oral administration.
Clinical pharmacokinetics 1992;22 Suppl 1():14-23.
-
1991: Granneman G R; Guay D R
The influence of age on the pharmacokinetics of temafloxacin.
The American journal of medicine 1991;91(6A):71S-75S.
-
1991: Granneman G R; Braeckman R; Kraut J; Shupien S; Craft J C
Temafloxacin pharmacokinetics in subjects with normal and impaired renal function.
Antimicrobial agents and chemotherapy 1991;35(11):2345-51.
-
1991: Granneman G R; Varga L L
High-performance liquid chromatographic procedures for the determination of temafloxacin in biological matrices.
Journal of chromatography 1991;568(1):197-206.
-
1991: Granneman G R; Carpentier P; Morrison P J; Pernet A G
Pharmacokinetics of temafloxacin in humans after single oral doses.
Antimicrobial agents and chemotherapy 1991;35(3):436-41.
-
1987: Granneman G R; Sennello L T
High-performance liquid chromatographic procedures for the determination of difloxacin and its metabolites in biological matrices.
Journal of chromatography 1987;413():199-206.
-
1986: Machinist J M; Bopp B A; Anderson D J; Granneman G R; Sonders R C; Tolman K; Buchi K; Rollins D
Metabolism of 14C-estazolam in dogs and humans.
Xenobiotica; the fate of foreign compounds in biological systems 1986;16(1):11-20.
-
1984: Granneman G R; Wang S I; Kesterson J W; Machinist J M
The hepatotoxicity of valproic acid and its metabolites in rats. II. Intermediary and valproic acid metabolism.
Hepatology (Baltimore, Md.) 1984;4(6):1153-8.
-
1984: Kesterson J W; Granneman G R; Machinist J M
The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies.
Hepatology (Baltimore, Md.) 1984;4(6):1143-52.
-
1984: Gibson T P; Granneman G R; Kallal J E; Sennello L T
Kinetics of cefsulodin in patients with renal impairment.
Reviews of infectious diseases 1984;6 Suppl 3():S689-97.
-
1984: Granneman G R; Wang S I; Machinist J M; Kesterson J W
Aspects of the metabolism of valproic acid.
Xenobiotica; the fate of foreign compounds in biological systems 1984;14(5):375-87.
-
1982: Granneman G R; Sennello L T
Precise high-performance liquid chromatographic procedure for the determination of cefsulodin, a new antipseudomonal cephalosporin antibiotic, in plasma.
Journal of pharmaceutical sciences 1982;71(10):1112-5.
-
1982: Gibson T P; Granneman G R; Kallal J E; Sennello L T
Cefsulodin kinetics in renal impairment.
Clinical pharmacology and therapeutics 1982;31(5):602-8.
-
1982: Granneman G R; Sennello L T
A very precise high-performance liquid chromatographic procedure for the determination of cefmenoxime, a new cephalosporin antibiotic, in plasma.
Journal of chromatography 1982;229(1):149-57.
-
1982: Granneman G R; Sennello L T; Sonders R C; Wynne B; Thomas E W
Cefsulodin kinetics in healthy subjects after intramuscular and intravenous injection.
Clinical pharmacology and therapeutics 1982;31(1):95-103.
-
1982: Granneman G R; Sennello L T; Steinberg F J; Sonders R C
Intramuscular and intravenous pharmacokinetics of cefmenoxime, a new broad-spectrum cephalosporin, in healthy subjects.
Antimicrobial agents and chemotherapy 1982;21(1):141-5.
Sign-in to see more
